- Home
- ALVR vs STTK Comparison
ALVR vs STTK Comparison
Compare ALVR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- STTK
- Stock Information
- Founded
- ALVR 2013
- STTK 2016
- Country
- ALVR United States
- STTK United States
- Employees
- ALVR N/A
- STTK N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ALVR Health Care
- STTK Health Care
- Exchange
- ALVR Nasdaq
- STTK Nasdaq
- Market Cap
- ALVR 52.2M
- STTK 54.4M
- IPO Year
- ALVR 2020
- STTK 2020
- Fundamental
- Price
- ALVR $0.40
- STTK $1.15
- Analyst Decision
- ALVR Sell
- STTK Hold
- Analyst Count
- ALVR 5
- STTK 3
- Target Price
- ALVR $1.00
- STTK $2.00
- AVG Volume (30 Days)
- ALVR 365.9K
- STTK 353.2K
- Earning Date
- ALVR 11-12-2024
- STTK 11-14-2024
- Dividend Yield
- ALVR N/A
- STTK N/A
- EPS Growth
- ALVR N/A
- STTK N/A
- EPS
- ALVR N/A
- STTK N/A
- Revenue
- ALVR N/A
- STTK $6,435,000.00
- Revenue This Year
- ALVR N/A
- STTK $313.04
- Revenue Next Year
- ALVR N/A
- STTK N/A
- P/E Ratio
- ALVR N/A
- STTK N/A
- Revenue Growth
- ALVR N/A
- STTK 382.75
- 52 Week Low
- ALVR $0.40
- STTK $0.94
- 52 Week High
- ALVR $1.05
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- ALVR 27.58
- STTK 46.55
- Support Level
- ALVR $0.40
- STTK $1.07
- Resistance Level
- ALVR $0.53
- STTK $1.19
- Average True Range (ATR)
- ALVR 0.04
- STTK 0.14
- MACD
- ALVR 0.00
- STTK 0.00
- Stochastic Oscillator
- ALVR 1.35
- STTK 36.11
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.